Skip to main content
Monday, November 16, 2026Nov 16

FDA needs better drug safeguards

Last month, the U.S. Food and Drug Administration requested the manufacturers of propoxyphene (PXP), a pain reliever, to stop selling drugs containing the substance. PXP was introduced in 1957, under the trade name of Darvon. Various derivatives quickly followed — Darvon Compound and Darvocet — which added other analgesics to the parent drug. At the time of the recall, an estimated 10 million Americans took PXP-containing drugs.

By itself, PXP was not particularly effective in relieving pain. The drug did seem to have an addictive risk. Stories circulated that PXP could extend or enhance the effect of narcotics.

The recall was based upon reports that PXP could cause dangerous disturbances in heart rhythm. Critics of PXP had argued for more than 20 years that the drug was unsafe for a variety of reasons. The vote by FDA overseers of product safety was 14 to 12, reflecting the controversy surrounding the issue. The United Kingdom and European Union banned PXP sales several years earlier.

PXP joins other recently recalled drugs with suspected, cardiac side effects. Rofecoxib (Vioxx) was recalled in September 2004 despite a spirited defense by its manufacturer that the drug was safe. The recall was based upon heart problems that appeared after 18 or more months of use of the drug.

More recently, the FDA issued new warnings of cardiac risks associated with the diabetes drug rosiglitazone (Avandia). The panel evaluating this drug was deeply divided over the issue of withdrawal versus restricted use of the agent.